#3016
DLL3 Is Expressed in GEP-Neuroendocrine Neoplasms with Loss of RB1 and Has Prognostic Significance
Introduction:
The negative notch regulator DLL3 has gained increasing attention in tumors with neuroendocrine features, in particular SCLC, LCNEC and neuroendocrine prostate cancer, both as prognostic marker and candidate therapeutic target. No data are available on the expression of DLL3 in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Liverani C
Authors:
Liverani C,
Bongiovanni A,
Pieri F,
Foca F,
Ravaioli S,
Keywords:
DLL3,
RB1,
prognostic biomarker,
GEP-NEN,
#2958
The Blood-based Multigenomic NETest Accurately Identifies Neuroendocrine Transformed Prostate Cancer
Introduction:
Neuroendocrine differentiation and an aggressive phenotype is an important feature of castration-resistant prostate cancer (CRPC). Current biomarkers are unable to detect these advanced, treatment refractory variants.
Conference:
17th Annual ENETSConcerence (2020)
Presenting Author:
Modlin I
Authors:
Modlin I,
Kidd M,
Rahbar K,
Malczewska A,
Rajwa P,
Keywords:
Biomarker,
NETest,
PSA,
prostate cancer,
neuroendocrine phenotype,
castration-resistance,
neuroendocrine,
#2173
Decreased Serum Amyloid A1 as Potential Diagnostic Marker for Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
Introduction:
Gastro-entero-pancreatic neuroendocrine neoplasms (GEP-NENs) are rare tumors with an increased incidence reported in recent years. Researchers have shown that tumor cells produce and secrete more exosomes compared with normal cells. Serum amyloid A1 (SAA1) is elevated in patients with liver cancer, lung cancer, breast cancer, prostate cancer and endometrial cancer. However, the relation between SAA1 and GEP-NENs remains unclear.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Qiyun T
Authors:
Na H,
Qiyun T,
Keywords:
Exosomes,
Serum amyloid A1,
Circulating biomarkers,
Diagnosis,
#2142
Preliminary Safety and Efficacy of Rovalpituzumab Tesirine in Patients with Delta-Like Protein 3-Expressing Advanced Solid Tumors
Introduction:
Rovalpituzumab tesirine (Rova-T™) is an antibody-drug conjugate targeting delta-like protein 3 (DLL3), an atypical Notch receptor family ligand expressed in high-grade neuroendocrine carcinomas (NECs).
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Mansfield A
Authors:
Mansfield A,
Aggarwal R,
Beltran H,
Farago A,
Hann C,
Keywords:
Rovalpituzumab tesirine,
DLL3,
neuroendocrine tumors,
antibody-drug conjugate,
